Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Atsena Therapeutics, a US-based gene therapy developer, launched yesterday with an $8.2m funding round backed by University of Florida (UF). The round was led by Hatteras Venture Partners with the involvement of spinout-focused investment firm Osage University Partners and RD Fund, a vehicle for research charity Foundation Fighting Blindness, with additional participation from PBM Capital. Atsena Therapeutics is developing a gene therapy for GUCY2D-associated Leber congenital amaurosis, a genetic eye disease that causes blindness in children. The drug has been…
